Our study provided nationwide-based evidence that starting TNF-α antagonists does not increase, but rather decreases, the risk of cancer for RA patients, in comparison with those taking nbDMARDs alone, with a reduction in 7-year cumulative incidence from 5.22% to 3.84%. This evidence concerns the gene TNF and rheumatoid arthritis.